NASDAQ: RARE CLASS ACTION NOTICE: Berger Montague Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified Class Period, highlighting concerns over misleading statements regarding clinical trial outcomes [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to investors who bought Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Clinical Trials and Impact - Throughout the Class Period, Ultragenyx made positive statements about the ORBIT and COSMIC Phase 3 programs, which were clinical trials for setrusumab as a treatment for Osteogenesis Imperfecta [3]. - On December 29, 2025, Ultragenyx revealed that neither clinical trial achieved its primary endpoint, leading to a significant drop in share price of over 42%, from $34.19 to $19.72 [4].